Brokerages Anticipate TapImmune Inc. (MRKR) Will Post Earnings of -$0.13 Per Share
Wall Street brokerages expect TapImmune Inc. (NASDAQ:MRKR) to post earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for TapImmune’s earnings. TapImmune reported earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 68.3%. The firm is scheduled to report its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that TapImmune will report full year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.58) to ($0.53). For the next financial year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.75) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover TapImmune.
TapImmune (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05.
Shares of MRKR stock opened at $5.72 on Monday. The company has a current ratio of 19.73, a quick ratio of 22.11 and a debt-to-equity ratio of 0.01. TapImmune has a one year low of $3.33 and a one year high of $13.55. The company has a market capitalization of $260.17 million, a PE ratio of -3.43 and a beta of -0.03.
A hedge fund recently bought a new stake in TapImmune stock. Personal Capital Advisors Corp bought a new position in shares of TapImmune Inc. (NASDAQ:MRKR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,712 shares of the company’s stock, valued at approximately $143,000. Personal Capital Advisors Corp owned approximately 0.06% of TapImmune as of its most recent SEC filing. 34.47% of the stock is owned by institutional investors.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Read More: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.